Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Alphamab/3D Medicines PD-L1 Antibody Approved for US Trial

publication date: Dec 1, 2016
Suzhou Alphamab and 3D Medicines (Sichuan) have received approval from the US FDA to begin clinical trials of KN035, a PD-L1 bi-specific immunotherapy. The two companies partnered on the molecule earlier this year: Alphamab discovered and developed the product, while 3D will be in charge of the clinical trials and commercialization. KN035 is a fusion protein of a PD-L1 single domain antibody and Fc. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital